[1] Slamon DJ, Godolphin W, Jones LA, et al.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J].Science, 1989, 244(4905):707-712.
[2] Cheng JC, Qiu X, Chang HM, et al.HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells[J].Biochem Biophys Res Commun, 2013, 434(1):81-86.
[3] Arai S, Meagher R, Swearingen M, et al.Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma:a phase Ⅰ trial[J].Cytotherapy, 2008, 10(6):625-632.
[4] Tam YK, Maki G, Miyagawa B, et al.Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy[J].Hum Gene Ther, 1999, 10(8):1359-1373.
[5] Uchino K, Ochiya T, Takeshita F.RNAi Therapeutics and applications of microRNAs in cancer treatment[J].Jpn J Clin Oncol, 2013, 43(6):596-607.
[6] 周颖, 凌斌, 高婷, 等.siRNA靶向Her-2逆转录病毒载体构建及其在SKOV3中的表达[J].肿瘤防治研究, 2007(4):277-280.
[7] 程志祥, 周颖, 朱园园, 等.靶向Her2基因SiRNA对人卵巢癌细胞株SKOV-3 顺铂敏感性的影响[J].安徽医科大学学报, 2007, 42(4):374-378.
[8] Chay WY, Chew SH, Ong WS, et al.HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer[J].PLoS One, 2013, 8(4):e61565.
[9] Yu M, Shi W, Zhang J, et al.Influence of reverse signaling via membrane TNF-α on cytotoxicity of NK92 cells[J].Eur J Cell Biol, 2009, 88(3):181-191.
[10] Liu XC, Liang H, Tian Z, et al.Proteomic analysis of human NK-92 cells after NK cell-mediated cytotoxicity against K562 cells[J].Biochemistry(Mosc), 2007, 72(7):716-727.
[11] 许恬怡, 凌斌, 陈纲, 等.放射线照射后NK-92 细胞对人宫颈癌细胞体外杀伤活性的研究[J].肿瘤防治研究, 2005, 32(6):336-338.